A Prospective Study of Plasma Homocyst(e)ine and Risk of Myocardial Infarction in US Physicians

JAMA: The Journal of the American Medical Association

Volumn 268, Issue 7, 1992, Pages 877-881

  Stampfer, Meir J ^a,b   Malinow, M Rene ^c,d   Willett, Walter C ^a,b   Newcomer, Laura M ^a   Upson, Barbara ^c   Ullmann, Daniel ^d   Tishler, Peter V ^a,e   Hennekens, Charles H ^a,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DRUG USE; HEART INFARCTION; HUMAN; HUMAN TISSUE; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MALE; MORTALITY; PHYSICIAN; PRIORITY JOURNAL; RISK FACTOR; STROKE; UNITED STATES; VITAMIN INTAKE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CORONARY DISEASE; HOMOCYSTEINE; HOMOCYSTINURIA; HUMAN; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; PHYSICIANS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.; UNITED STATES;

EID: 0026684554     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1992.03490070059042     Document Type: Article

References (36)

1. 1. Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In: Scriver CS, Beaudet AL, Sly WL, Valle D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill International Book Co; 1989:693-734.
2. 2. Malinow MR. Hyperhomocyst(e)inemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation. 1990;81:2004-2006.
3. 3. Malinow MR. Homocyst(e)ine and vascular occlusive disease. Nutr Metabol Cardiovasc Dis. 1992; 1:166-169.
4. 4. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
5. 5. Stampfer MJ, Buring JE, Willett W, Rosner B, Eberlein K, Hennekens CH. The2×2factorial design: its application to a randomized trial of aspirin and carotene in US physicians. Stat Med. 1985;4:111-116.
6. 6. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129-135.
7. 7. IHD Registers: Report of the Fifth Working Group. Copenhagen, Denmark: World Health Organization; 1971.
8. 8. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
9. 9. Katrangi N, Kaplan LA, Stein EA. Separation and quantitation of β-carotene and other carotenoids by high performance liquid chromatography. J Lipid Res. 1984;25:400-406.
10. 10. Polansky MM, Reynolds RD, Vanderslice JT. Vitamin B6. In: Augustine J, Klein BP, Becher DA, Venugopal PB, eds. Methods of Vitamin Assay. 4th ed. New York, NY: John Wiley & Sons Inc; 1985: 417-445.
11. 11. Smolin LA, Schneider JA. Measurement of total plasma cysteamine using high-performance liquid chromatography with electrochemical detection. Anal Biochem. 1988;168:374-379.
12. 12. Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989;79:1180-1188.
13. 13. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)ine in daily practice: levels in coronary artery disease. Coronary Artery Dis. 1990;1:215-220.
14. 14. Storer BE, Wacholder S, Breslow NE. Maximum likelihood fitting of general risk models to stratified data. Appi Stat. 1983;32:172-181.
15. 15. Mereau-Richard C, Muller JP, Faivre E, Ardouin P, Rousseaux J. Total plasma homocysteine determination in subjects with premature cerebral vascular disease. Clin Chem. 1991;37:126.
16. 16. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest. 1976;57:1079-1082.
17. 17. Kang SS, Wong PWK, Cook HY, Norusis M, Messer JV. Protein bound homocyst(e)ine—a possible risk factor for coronary artery disease. J Clin Invest. 1986;77:1482-1486.
18. 18. Murphy-Chutorian DR, Wexman MP, Grieco AJ, et al. Methionine intolerance: a possible risk factor for coronary artery disease. J Am Coll Cardiol. 1985;6:725-730.
19. 19. Genest JJ Jr, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990;16:1114-1119.
20. 20. Genest JJ Jr, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterio Throm. 1991;11:1129-1136.
21. 21. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis. 1988;71:227-233.
22. 22. Williams RR, Malinow MR, Hunt SC, et al. Hyperhomocyst(e)inemia in Utah siblings with early coronary disease. Coronary Artery Dis. 1990;1:681-685.
23. 23. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989;114:473-501.
24. 24. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Throm Res. 1980;18:113-121.
25. 25. DeGroot PG, Willems C, Boers GH, Gonsalves MD, Van Aken WG, Van Mourik JA. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest. 1983;13:405-410.
26. 26. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986; 77:1370-1376.
27. 27. Reed T, Malinow MR, Christian JC, Upson B. Estimates of heritability for plasma homocyst(e)ine levels in aging adult male twins. Clin Genet. 1991;39:425-428.
28. 28. Rubba P, Faccenda F, Pauciullo P, et al. Early signs of vascular disease in homocystinuria: a noninvasive study by ultrasound methods in eight families with cystathionine-beta synthase deficiency. Metabolism. 1990;39:1191-1195.
29. 29. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991; 48:536-545.
30. 30. Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism. 1987; 36:458-462.
31. 31. Brattstrom L, Israelsson B, Lindgärde F, Hultberg B. Higher total plasma homocysteine in vitamin B 12 deficiency than in heterozygosity for homocystinuria due to cystathionine β-synthase deficiency. Metabolism. 1988;37:175-178.
32. 32. Subar AF, Block G, James LD. Folate intake and food sources in the US population. Am J Clin Nutr. 1989;50:508-516.
33. 33. Manore MM, Vaughan LA, Carroll SS, Leklem JE. Plasma pyridoxal 5′phosphate concentration and dietary vitamin B6 intake in free-living, low-income elderly people. Am J Clin Nutr. 1989;50: 339-345.
34. 34. Brattstrom LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic acid—an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest. 1988;48:215-221.
35. 35. Smolin LA, Benevenga NJ, Berlow S. The use of betaine for the treatment of homocystinuria. J Pediatr. 1981;99:467-472.
36. 36. Wilcken DEL, Dudman NPB, Tyrrell PA. Homocystinuria due to cystathionine βsynthase deficiency—the effects of betaine treatment in pyridoxine-responsive patients. Metabolism. 1985; 34:1115-1121.